2096980-79-7
英文名称
L-Lysine, L-leucyl-L-α-glutamyl-L-α-glutamyl-L-serylglycylglycylglycyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycylglycyl-L-seryl-L-methionyl-
CAS
2096980-79-7
分子式
C64H108N18O24S
更新日期
2024/01/10 16:36:18
分子量
1545.73
MOL 文件
2096980-79-7.mol
2096980-79-7 结构式
基本信息
英文别名
LEESGGGLVQPGGSMKL-Lysine, L-leucyl-L-α-glutamyl-L-α-glutamyl-L-serylglycylglycylglycyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycylglycyl-L-seryl-L-methionyl-
物理化学性质
沸点1987.2±65.0 °C(Predicted)
密度1.334±0.06 g/cm3(Predicted)
酸度系数(pKa)3.25±0.10(Predicted)
序列Leu-Glu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-Ser-Met-Lys
常见问题列表
生物活性
LEESGGGLVQPGGSMK，一种蛋白水解肽，是 Infliximab 的一种成分，可用于 Infliximab 的定量分析。Infliximab 是一种与 TNF-α 特异性结合的嵌合单克隆 IgG1 抗体。体外研究
The anti-TNF antibodies blocking the action of TNF alpha revolutionized therapy of TNF-related diseases such as Inflammatory Bowel Disease, lupus, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis. By neutralizing TNF activity, anti-TNF antibodies promote mucosal healing and induce long-term remissions in vivo. The main anti-TNF antibodies that are currently authorized encompass Infliximab, Etanercept, Adalimumab, Certolizumab and Golimumab.